This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| psychedelic drugs | |
|---|---|
| Name | Psychedelic drugs |
| Synonyms | Hallucinogens |
| Routes of administration | Oral, smoked, insufflated, intravenous |
| Legal status | Varies by country |
psychedelic drugs Psychedelic drugs are a class of psychoactive substances that produce profound alterations in perception, mood, and cognition. They have been used in religious contexts, explored in 20th‑century scientific research, and are the subject of contemporary clinical trials and legal debates. Prominent figures, institutions, and events have shaped public and scientific understanding of these compounds.
Psychedelic drugs encompass substances such as N,N‑dimethyltryptamine, lysergic acid diethylamide, psilocybin, mescaline, and ketamine that interact with neural systems to induce altered states. Early ethnobotanical use involved cultures associated with the Mesoamerica, Andes Mountains, Siberia, and Amazon Rainforest regions where ritual leaders employed naturally occurring psychedelics. In the 20th century, researchers at institutions like Harvard University, Johns Hopkins University, and the Imperial College London conducted experimental studies alongside clinicians from the National Institute of Mental Health and private laboratories. Notable personalities linked to the field include Albert Hofmann, Alexander Shulgin, Timothy Leary, and Stanislav Grof.
Prehistoric and historical use is documented in archaeological finds and colonial accounts tied to peoples such as the Aztec Empire, Inca Empire, and Indigenous groups of the Pacific Northwest. Botanical sources like the Psilocybe fungi, Peyote cactus (used by the Huichol people), and ayahuasca preparations in Peru and Brazil underpin long traditions. In the modern era, discoveries by Albert Hofmann at Sandoz Laboratories and the synthesis work of Alexander Shulgin influenced both scientific and countercultural movements associated with events such as the Summer of Love and institutions like the Esalen Institute. Regulatory shifts followed incidents involving the Controlled Substances Act and international treaties negotiated by bodies including the United Nations. Renewed clinical interest emerged in the late 20th and early 21st centuries with trials at centers such as Imperial College London and Johns Hopkins University.
Many classic psychedelics act as agonists or partial agonists at the 5‑HT2A receptor on cortical pyramidal neurons, a mechanism explored using techniques derived from laboratories associated with Cold Spring Harbor Laboratory and imaging at facilities like the National Institutes of Health Clinical Center. Other targets include serotonin transporter interactions and modulation of thalamocortical circuits studied with methods developed at Massachusetts Institute of Technology and Stanford University. Dissociative substances linked to the NMDA receptor show distinct receptor pharmacology investigated by researchers affiliated with Columbia University and the Salk Institute. Contemporary neuroimaging work by teams at University College London and Yale University examines network‑level effects such as changes in the default mode network.
Representative compounds span chemical families and sources: - Tryptamines: N,N‑dimethyltryptamine (DMT), psilocybin from Psilocybe species; associated researchers include Rick Strassman. - Ergoline derivatives: lysergic acid diethylamide (LSD) synthesized by Albert Hofmann at Sandoz Laboratories. - Phenethylamines: mescaline from Peyote cactus and synthetic analogues cataloged by Alexander Shulgin. - Dissociatives: ketamine used clinically in settings including Massachusetts General Hospital and experimental trials at Yale University. - Empathogens/entactogens: MDMA investigated in trials with oversight from organizations like the Multidisciplinary Association for Psychedelic Studies (MAPS).
Acute effects include perceptual shifts, altered sense of self, and emotional variability documented in case series from hospitals such as Mount Sinai Hospital and emergency departments across metropolitan centers like New York City and London. Risks span psychological adverse reactions, precipitating or exacerbating conditions in individuals with a family history involving institutions like the American Psychiatric Association and medical contraindications managed by clinics affiliated with Johns Hopkins University. Physiological hazards and interactions with prescription medications have been cataloged in pharmacovigilance records involving agencies such as the Food and Drug Administration and European Medicines Agency.
Clinical research explores therapeutic potential for disorders including treatment‑resistant depression, posttraumatic stress disorder, and substance use disorders in trials led by teams at Johns Hopkins University, Imperial College London, University of California, San Francisco, and MAPS. Regulatory milestones include breakthrough therapy designations by the Food and Drug Administration and investigator‑initiated protocols approved by institutional review boards at universities like NYU School of Medicine. Historical psychotherapy paradigms were advanced by figures such as Stanislav Grof and revived in modern randomized controlled trials evaluating efficacy, dosing paradigms, and long‑term outcomes.
Legal frameworks vary: statutes such as the Controlled Substances Act in the United States and scheduling decisions by the European Commission affect availability, while municipal initiatives in cities like Denver and Oakland, California have altered local enforcement. International control is shaped by treaties administered by bodies such as the United Nations Office on Drugs and Crime and national scheduling conducted by agencies like the Drug Enforcement Administration and Health Canada.
Category:Psychedelics